research Immune-Mediated Skin Reactions Induced by Recombinant Antibodies and Other TNF-Alpha Inhibitors
TNF-alpha inhibitors can cause various immune-related skin issues.
Search
for
Sort by
Research
240-270 / 1000+ results 
research Severe cutaneous adverse reactions to drugs
Some drugs can cause rare but potentially deadly skin reactions, and early treatment and avoiding the drug again are key.
research 586 Increase in CD8+ effector memory cells re-expressing CD45RA (TEMRA) reflects disease activity and enables early prediction of therapeutic outcome in rapidly progressive alopecia areata
Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Learning From Success and Failure: Biologics for Non-approved Skin Diseases
Biologics show promise in treating various stubborn skin diseases, but more research and better reimbursement criteria are needed.
research Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
research Supplementary Material for: Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study
RCS-01 cell therapy is safe and improves skin gene expression.
research Madarosis and facial keratinaceous spines
Reducing immunosuppression and using antiviral creams improved the woman's skin condition.
research 706 Predictive modeling of patient response to JAK/STAT inhibitors and dynamic patient-matching
Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
research Approved systemic drugs needed for dermatosis like alopecia areata, hidradenitis and vitiligo: A SPIN ‐FRT evaluation
More effective treatments are needed for alopecia areata, hidradenitis suppurativa, and vitiligo.
research 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
Targeted cancer therapies can cause skin side effects, but activating SOS in the skin may help reduce them.
research Update on Outcome Measures for Pediatric Systemic Lupus Erythematosus
New tools and criteria have been developed to better assess and treat pediatric lupus.
research Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
research Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
research Scalp-sparing total skin electron therapy in mycosis fungoides: Case report highlighting technique and outcome
Total skin electron therapy is an effective treatment for mycosis fungoides, balancing effectiveness and side effects.
research Severe pustular lesions induced by topical immunotherapy with squaric acid dibutylester for alopecia totalis
Squaric acid dibutylester can cause severe skin reactions in people with allergies.
research Supplementary Material for: Immunotherapy-Induced Scarring Alopecia: A Case Series
Immune therapy for cancer can cause hair loss scars in some patients.
research Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.
research Plain Language Summaries
Most clinicians follow discharge guidelines, many lupus patients don't use sunscreen regularly, dithranol is effective for psoriasis, biopsy methods should be based on lesion type, voriconazole may raise skin cancer risk, a new scale can help diagnose female hair loss early, and most melanomas may develop from existing moles.
research Cutaneous toxicities of new treatments for melanoma
New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
research Cutaneous side effects caused by treatment for inflammatory bowel disease
Some treatments for inflammatory bowel disease can cause skin problems like rashes and melanoma.
research P368 Rare skin disorders in IBD patients treated with anti-TNFs
Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
Cancer treatments often cause skin, nail, and hair problems.
research Graft-versus-host reaction. Cutaneous manifestations following bone marrow transplantation.
Skin changes help detect graft-versus-host reaction early after bone marrow transplants.
research Identification of drug-specific public TCR driving severe cutaneous adverse reactions
Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
research Skin diseases in Turkish renal transplant recipients
Most kidney transplant patients in the study had skin problems, often related to infections, medication side effects, or skin cancer risks.
research Adverse Reactions Following Intradermal Injection of Exosome‐Based Formulations: A Case Series
Unregulated exosome-based injections can cause severe skin reactions and scarring.
research Prophylaxis and Management of Skin Toxicities
Preventive measures and effective management are crucial for reducing skin side effects in cancer treatment.
research Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.